What is the best time for 18F-FDG-PET evaluation in estrogen receptor-negative and HER2-positive breast cancer patients receiving neoadjuvant trastuzumab and pertuzumab?
作者信息
Altundag Kadri
机构信息
MKA Breast Cancer Clinic, Tepe Prime, Cankaya, 06800 Ankara, Turkey.
出版信息
J BUON. 2021 Jul-Aug;26(4):1685.
PMID:34565040
Abstract
摘要
Zotero 插件